Abstract
First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have